Bornstein SR, Rubino F, Ludwig B, Rietzsch H, Schwarz PEH, Rodionov RN, Khunti K, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RIG, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Geloneze B, Chan JC, Mbanya JC, Onyegbutulem HC, Ramachandran A, Basit A, Hassanein M, Spinas GA, Beuschlein F, Mingrone G. Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nat Metab. 2021 Feb 25. doi: 10.1038/s42255-021-00358-y. Epub ahead of print. PMID: 33633407. https://doi.org/10.1038/s42255-021-00358-y
Patients with metabolic diseases are facing increased challenges in the COVID-19 pandemic, as a consequence of the prolonged lockdown, the exhaustion of healthcare systems, the viral disease itself and the effects of medications introduced for the treatment of SARS-CoV-2 infection. COVID-19 and metabolic disease currently cause substantial collateral damage for patients and pose new challenges to the entire metabolic health community that must be addressed. We, as a global team of experts representing six continents, are united in our views that we must raise our voices, given the current catastrophic situation that we are currently facing in caring for our patients. Decreased access to primary-care providers and a high demand for the care of critically ill patients with COVID-19 divert hospital staff and resources, which consequently are lacking in other areas of care. This situation poses a substantial risk for all patients with chronic diseases, particularly those with chronic metabolic disease. Below, we outline the main areas that, in our view, demand more attention or further consideration.
Link da publicação
